TWI232749B - Preparations stabilized over long time - Google Patents
Preparations stabilized over long time Download PDFInfo
- Publication number
- TWI232749B TWI232749B TW089103623A TW89103623A TWI232749B TW I232749 B TWI232749 B TW I232749B TW 089103623 A TW089103623 A TW 089103623A TW 89103623 A TW89103623 A TW 89103623A TW I232749 B TWI232749 B TW I232749B
- Authority
- TW
- Taiwan
- Prior art keywords
- csf
- pharmaceutical composition
- scope
- patent application
- residual rate
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title description 67
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims abstract description 121
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims abstract description 121
- 238000012360 testing method Methods 0.000 claims abstract description 58
- 230000007774 longterm Effects 0.000 claims abstract description 30
- 238000003860 storage Methods 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 229940024606 amino acid Drugs 0.000 claims description 57
- 235000001014 amino acid Nutrition 0.000 claims description 57
- 150000001413 amino acids Chemical class 0.000 claims description 56
- 235000018102 proteins Nutrition 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 34
- -1 threonine Amino acids Chemical class 0.000 claims description 33
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 29
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 29
- 235000008729 phenylalanine Nutrition 0.000 claims description 29
- 238000011049 filling Methods 0.000 claims description 28
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 26
- 229930182817 methionine Natural products 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- 239000004475 Arginine Substances 0.000 claims description 21
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 21
- 235000009697 arginine Nutrition 0.000 claims description 21
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 20
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 18
- 239000004472 Lysine Substances 0.000 claims description 18
- 235000018977 lysine Nutrition 0.000 claims description 18
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 17
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 17
- 235000003704 aspartic acid Nutrition 0.000 claims description 17
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 16
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 16
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 16
- 235000013922 glutamic acid Nutrition 0.000 claims description 16
- 239000004220 glutamic acid Substances 0.000 claims description 16
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 15
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 13
- 239000004473 Threonine Substances 0.000 claims description 13
- 230000002079 cooperative effect Effects 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 235000008521 threonine Nutrition 0.000 claims description 13
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 12
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 12
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 12
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 12
- 235000009582 asparagine Nutrition 0.000 claims description 12
- 229960001230 asparagine Drugs 0.000 claims description 12
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 11
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 11
- 235000014304 histidine Nutrition 0.000 claims description 11
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 11
- 239000003381 stabilizer Substances 0.000 claims description 11
- 239000007800 oxidant agent Substances 0.000 claims description 10
- 229940063675 spermine Drugs 0.000 claims description 10
- 239000005871 repellent Substances 0.000 claims description 9
- 229960001340 histamine Drugs 0.000 claims description 8
- 230000001590 oxidative effect Effects 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 238000012423 maintenance Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 125000003277 amino group Chemical group 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 11
- 229960003121 arginine Drugs 0.000 description 18
- 229960003646 lysine Drugs 0.000 description 14
- 229960005261 aspartic acid Drugs 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 229960002898 threonine Drugs 0.000 description 11
- 229960002989 glutamic acid Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 229960002885 histidine Drugs 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 235000004554 glutamine Nutrition 0.000 description 4
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 4
- 229950008882 polysorbate Drugs 0.000 description 4
- 235000004400 serine Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000002374 tyrosine Nutrition 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WOKDXPHSIQRTJF-UHFFFAOYSA-N 3-[3-[3-[3-[3-[3-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)CO WOKDXPHSIQRTJF-UHFFFAOYSA-N 0.000 description 3
- 240000008564 Boehmeria nivea Species 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 3
- 239000004062 cytokinin Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- 229960001319 parathyroid hormone Drugs 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000013930 proline Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical group CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004147 Sorbitan trioleate Substances 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 description 2
- 229960000391 sorbitan trioleate Drugs 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PBTPTBMYJPCXRQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;hexadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCC(O)=O PBTPTBMYJPCXRQ-MGMRMFRLSA-N 0.000 description 1
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100030851 Cortistatin Human genes 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 238000001162 G-test Methods 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 102400001357 Motilin Human genes 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101710138332 Somatostatin-2 Proteins 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940088990 ammonium stearate Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical compound [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- QSLMXDUZJAJNJO-UHFFFAOYSA-L disodium hydrogen phosphate phosphoric acid Chemical compound [Na+].[Na+].OP(O)(O)=O.OP(O)(O)=O.OP([O-])([O-])=O QSLMXDUZJAJNJO-UHFFFAOYSA-L 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940071180 lauryl sulfosuccinate Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical class CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N ornithyl group Chemical group N[C@@H](CCCN)C(=O)O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- MWZFQMUXPSUDJQ-KVVVOXFISA-M sodium;[(z)-octadec-9-enyl] sulfate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCCOS([O-])(=O)=O MWZFQMUXPSUDJQ-KVVVOXFISA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- GGYTXJNZMFRSLX-DFTNLTQTSA-N somatostatin-28 Chemical compound N([C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC1)C(O)=O)[C@@H](C)O)[C@@H](C)O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CO GGYTXJNZMFRSLX-DFTNLTQTSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 125000001990 thiamine group Chemical group 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Amplifiers (AREA)
- Signal Processing For Digital Recording And Reproducing (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Fodder In General (AREA)
Description
1232749 A7 B7 五、發明說明(1 ) 技術領域 本發明爲關於G - C S F (粒性細胞菌落刺激因子) 製劑,且特別爲關於長期保存後亦令活性成分之損失少, 且G - C S F的甲硫胺酸殘基之氧化體生成率低之安定化 的G — C S F製劑。 背景技術 G - C S F爲作用於嗜中性白血球的前驅細胞,且促 進其增殖及分化成熟之分子量約2萬的糖蛋白質。
經由本申請人,將口腔底癌患者的腫瘤細胞所採集之 細胞株予以培養,精製高純度之人類G - C S F以來,其 契機地成功克隆出人類G - C S F基因,且使得現在可經 由基因工程學之方法,於微生物和動物細胞中大量生產重 組之G - C S F。又,本案申請人將此精製的G — C S F 成功的製劑化,並將其以預防感染劑型式於市場上供給製 品(專利第2 1 1 6 5 1 5號)。 G - C S F爲以極微量使用,通常成人每一人,將含 有0 · 1〜1 000微克(較佳爲5〜5 0 0微克)G — C S F之製劑以1〜7回/週之比例進行投藥。但是,此 G - C S F例如對於注射用安瓿、注射器等之器壁顯示出 吸附性。又,G - C S F爲不安定’且易受外來因子影響 ,並且因溫度、濕度、氧氣、紫外線等則產生會合、聚合 或氧化等物理性、化學性變化’其結果導致活性大爲降低 (請先閱讀背面之注意事項再填寫本頁) 1111111_
經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -4- 1232749 A7 _ B7 五、發明說明(2 ) (請先閱讀背面之注意事項再填寫本頁) 於是,爲了對市場供給安定的G - C S F製劑,乃進 行各種的配方設計。例如,提案含有(a )由蘇胺酸、色 胺酸、離胺酸、羥基離胺酸、組胺酸、精胺酸、半胱胺酸 、胱胺酸、甲硫胺酸所選出之至少一種胺基酸;(b )至 少一種之含硫還原劑;或(c )至少一種之抗氧化劑,所 組成之群中選自至少一種之製劑(專利第2 5 7 7 7 4 4 號)等。又,已有含有以聚山梨酸酯等界面活性劑作爲安 定劑的G — C S F製劑(特開昭6 3 — 1 4 6 8 2 6號) 〇 又,由減少對於容器的附著,抑制化學性變化之觀點 而言,其有利作成冷凍乾燥製劑,且亦已報導含有麥芽糖 、鼠李糖、蔗糖、海藻糖或胺基糖之G - C S F冷凍乾燥 製劑(特表平8 - 5 0 4 7 8 4號)。
現在市場所供給的製品,爲了抑制其化學性、物理性 變化,乃添加一般所使用之人類血淸白蛋白或精製之明膠 等蛋白質作爲安定劑。但是,關於添加蛋白質作爲安定齊ij ’則具有必須除去病毒污染物等非常煩雜工程等之問題。 經濟部智慧財產局員工消費合作社印製 但是,於不添加此類蛋白質之情形中,則多生成G -C S F之甲硫胺酸殘基的氧化體,帶來令品質惡化之問題 發明之揭示 本發明之目的爲在於提供即使長期保存亦爲安定,且 G - C S F之甲硫胺酸殘基的氧化體生成率低之G - -5- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1232749 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(3 ) c S F製齊ϋ。 爲了達成上述目的進行致力硏究,結果本發明者等人 經由組合添加特定之胺基酸作爲安定劑,則發現即使於長 期保存後亦令G — C S F殘存率筒,且G — C S F之甲石荒 胺酸殘基的氧化體生成率低之G - C S F製劑,並且完成 本發明。 即’本發明爲提供2 5 C - 3個月長期保存g式驗後之 G — CSF殘存率爲90%以上,40 °C- 2個月長期保 存試驗後之G - C S F殘存率爲9 0 %以上,5 0 °C — 1 個月之加速試驗後之G - C S F殘存率爲9 0 %以上, 6 0°C - 2週之加速試驗後之G - C S F殘存率爲9 0% 且5 0 °C — 1個月之加速試驗後或6 0 °C — 2週之加速試 驗之G - C S F的甲硫胺酸殘基氧化體生成率爲1 %以下 之安定的G—CSF製劑。 本發明爲再提供則述之G - C S F製劑,其中含有由 離胺酸、組胺酸、精胺酸、天冬胺酸、麩胺酸、蘇胺酸、 天冬醯胺所組成群中選出一種以上之胺基酸、及由斥水性 胺基酸所選出之一種以上之胺基酸、及甲硫胺酸。 本發明爲再提供前述之G - C S F製劑,其中斥水性 胺基酸爲選自苯基丙胺酸、色胺酸及白胺酸。 本發明爲再提供刖述之G - C S F製劑,其爲含有由 離胺酸、組胺酸、精胺酸、天冬胺酸、麩胺酸所組成群中 選出一種以上之胺基酸、及由苯基丙胺酸、色胺酸及白胺 酸所組成群中選出一種以上之胺基酸、及甲硫胺酸。 (請先閱讀背面之注意事項再填寫本頁) -· 訂---------
本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -6 - 經濟部智慧財產局員工消費合作社印製 1232749 A7 ___B7_____ 五、發明說明(4 ) 本發明爲再提供前述之G - C S F製劑’其含有苯基 丙胺酸、精胺酸及甲硫胺酸。 本發明爲再提供前述之G - C S F製劑’其中安定劑 爲實質上不含蛋白質。 本發明爲再提供前述之G - C S F製劑,其爲冷凍乾 燥製劑。 本發明爲再提供前述之G - C S F製劑,其爲再含有 甘露醇。 本發明爲再提供前述之G - C S F製劑’其爲再含有 界面活性劑。 本發明爲再提供前述之G - C S F製劑,其中界面活 性劑爲聚氧乙烯山梨糖醇酐烷酯。 本發明爲再提供前述之G 一 C S F製劑,其中界面活 性劑爲聚山梨酸酯2 0和/或8 0。 本發明爲再提供前述之G — C S F製劑,其中pH爲 5〜7。
本發明爲再提供前述之G - C S F製劑,其中pH 5 · 5 〜6 · 8 〇 本發明爲再提供前述之G — C S F製劑,其中pH爲 6 · 5 〇 本發明爲再提供前述之G — C S F製劑,其中G — C S F爲由C Η〇細胞所產生的G — C S F。 本發明爲再提供安定的G - C S F製劑,其特徵爲含 有由離胺酸、組胺酸、精胺酸、天冬胺酸、麩胺酸、蘇胺 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
1232749 A7 ____B7_ 五、發明說明(5 ) 酸、天冬醯胺所組成群中選出一種以上之胺基酸、及由斥 水性胺基酸所選出之一種以上胺基酸,且p Η 5〜7之 2 5 °C - 3個f長期保存試驗後之G — C S F殘存率爲 9 0 %以上,4 0 °C — 2個月長期保持試驗後之G — C S F殘存率爲9 0 %以上,5 0 t — 1個月之加速試驗 後之G — CSF殘存率爲90%以上,60°C - 2週之加 速試驗後之G - C S F殘存率爲9 0%以上之安定的G -C S F製劑。 本發明爲再提供安定的G - C S F製劑,其特徵爲含 有由離胺酸、組胺酸、精胺酸、天冬胺酸、麩胺酸所組成 群中選出一種以上之胺基酸、及苯基丙胺酸、色胺酸及白 胺酸所組成群中選出一種以上之胺基酸,且p Η爲5〜7 之2 5 t - 3個月長期保存試驗後之G — C S F殘存率爲 9〇%以上,4 0 t: — 2個月長期保持試驗後之G — C S F殘存率爲9 0%以上,5 0°C — 1個月之加速試驗 後之G — CSF殘存率爲90%以上,60 °C - 2週之加 速試驗後之G - C S F殘存率爲9 0%以上之安定的G -C S F製齊ij。 本發明爲再提供前述任一項之G - C S F製劑,其中 P Η 爲 6 · 5。 本發明爲再提供該蛋白質之甲硫胺酸殘基氧化體生成 之抑制方法,其特徵爲於含有具甲硫胺酸殘基生理活性蛋 白質之組成物中,添加甲硫胺酸。 本發明爲再提供前述之方法,其中生理活性蛋白質爲 (請先閱讀背面之注意事項再填寫本頁) _*
經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -8- 1232749 A7 B7 五、發明說明(6 ) 細胞激動素或生理活性生肽。 本發明爲再提供前述之方法,其中生理活性蛋白質爲 菌落刺激因子或P T Η。 本發明爲再提供前述之方法,其中生理活性蛋白質爲 G - CSF,促紅血球生成素或ΡΤΗ。 本發明爲再提供前述之方法,其特徵爲不含有其他蛋 白質作爲安定劑。 本發明爲再提供前述之方法,其特徵爲含有具甲硫胺 酸殘基生理活性蛋白質之組成物爲被冷凍乾燥或爲溶液狀 肯g 〇
>QiN 本發明爲再提供含有具甲硫胺酸殘基生理活性蛋白質 之安定化組成物,其爲含有甲硫胺酸及一種以上之其他胺 基酸。 本發明爲再提供前述含有具甲硫胺酸殘基生理活性蛋 白質之安定化組成物,其中胺基酸爲由離胺酸、組胺酸、 精胺酸、天冬胺酸、麩胺酸、苯基丙胺酸、色胺酸、白胺 酸、異白胺酸、纈胺酸、丙胺酸、脯胺酸、甘胺酸、絲胺 酸、蘇胺酸、天冬醯胺、麩胺醯胺及酪胺酸所組成群中選 出一種或二種以上。 本發明爲再提供前述含有具甲硫胺酸殘基之生理活性 蛋白質之安定化組成物,其特徵爲不含有其他蛋白質作爲 安定劑。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
ϋ n 一I 1 em— I eat ί ϋ I 經濟部智慧財產局員工消費合作社印製 -9- 經濟部智慧財產局員工消費合作社印製 1232749 A7 ____B7 _ 五、發明說明(8 ) )細胞、c 1 2 7細胞等之來自動物的培養細胞等中產生 ,並以各種方法進行萃取、分離精製。較佳爲以大腸桿菌 、酵母菌或C Η 0細胞使用基因重組法所產生者。最佳爲 以C Η 0細胞使用基因重組法所產生者。 本發明之G - C S F製劑中,較佳之安定劑爲人類血 淸白蛋白和精製明膠等之實質上不含蛋白質者。 本發明之G - C S F製劑爲於2 5 t: — 3個月長期保 存試驗後之G - C S F殘存率爲9 0 %以上,較佳爲9 5 %以上,4 0 °C — 2個月長期保存試驗後之G — C S F殘 存率爲9 5 %以上,4 0 °C - 2個月長期保存試驗後之G 一 CSF殘存率爲90%以上,較佳爲95%以上,50 °C 一 1個月之加速試驗後之G — C S F殘存率爲9 0 %以 上,較佳爲9 5 %以上,6 0 °C - 2週之加速試驗後之G 一 C S F殘存率爲9 0%以上,較佳爲9 5%以上,且 5〇°C 一 1個月之加速試驗後或6 0 °C — 2週之加速試驗 之G - C S F的甲硫胺酸殘基氧化體生成率爲1 %以下, 較佳爲檢測界限以下,比先前已知之G - C S F製劑爲極 安定的製劑。 本發明之G - C S F製劑之一例爲含有由離胺酸、組 胺酸、精胺酸、天冬胺酸、麩胺酸、蘇胺酸、天冬醯胺所 組成群中選出一種以上之胺基酸,較佳爲由離胺酸、組胺 酸、精胺酸、天冬胺酸、麩胺酸所組成群中選出一種以上 之胺基酸,及由斥水性胺基酸所選出之一種以上之胺基酸 ,較佳爲苯基丙胺酸、色胺酸及白胺酸所組成群中選出一 (請先閱讀背面之注意事項再填寫本頁)
本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -11 - 1232749 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(9 ) 種以上之胺基酸、及甲硫胺酸之G 一 c S F製劑。 更且,本發明之G- C S F製劑之一例爲含有由離胺 酸、組胺酸、精胺酸、天冬胺酸、麩胺酸、蘇胺酸、天冬 醯胺所組成群中選出一種以上之胺基酸,較佳爲由離胺酸 、組胺酸、精胺酸、天冬胺酸、麩胺酸所組成群中選出一 種以上之胺基酸’及由斥水性胺基酸所選出之一種以上之 胺基酸’較佳爲苯基丙胺酸、色胺酸及白胺酸所組成群中 選出一種以上之胺基酸、及甲硫胺酸,且P Η爲5〜7爲 牛寸Μ之2 5 C - 3個月長期保存試驗後之G - C S F殘存 率爲9 0 %以上,4 0 °C — 2個月長期保持試驗後之G - C S F殘存率爲9 〇 %以上,5 0 °C — 1個月之加速試驗 後之G — CSF殘存率爲90%以上,60°C — 2週期間 之加速試驗後之G — C S F殘存率爲9 0%且5 0°C — 1 個月之加速試驗後或6 0 °C - 2週之加速試驗後之G -C S F的甲硫胺酸殘基氧化體生成率爲1 %以下之安定的 G — C S F製劑。 本發明所使用之胺基酸爲包含游離之胺基酸及其鈉鹽 、鉀鹽、鹽酸鹽等鹽。於本發明之製劑中,包含此些胺基 酸之D -、L 一及DL —體,且更佳爲L 一體及其鹽。 本發明製劑中所添加之胺基酸的添加量,可根據所使 用之胺基酸種類,使用後述之試驗方法決定較佳之範圍。 一般之最終投予量爲0·001〜50毫克/毫升。例如 ,苯基丙胺酸較佳爲以0·1〜25毫克/毫升,更佳爲 1〜20毫克/毫升,精胺酸較佳爲0 · 1〜25毫克/ (請先閱讀背面之注意事項再填寫本頁) - ·11111111
本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -12- 1232749 A7 -----B7_ 五、發明說明(1〇 ) <升’更佳爲1〜2 0毫克/毫升,甲硫胺酸較佳爲 0·001〜5毫克/毫升,更佳爲〇·01〜4毫克/ 毫升。 於本發明之製劑中,等張化劑可使用聚乙二醇、葡聚 糖、甘露醇、山梨糖醇、肌醇、葡萄糖、果糖、乳糖、木 Μ、甘露糖、麥芽糖、蔗糖、鼠李糖等糖類。以甘露醇爲 特佳。甘露醇之添加量於製劑中爲以1〜1 0 0毫克/毫 升,較佳爲5〜6 0毫克/毫升。 於本發明之製劑中可再含有界面活性劑。界面活性劑 方令非離子界面活性劑例如爲山梨糖醇酐單辛酸酯、山梨糖 醇酐單月桂酸酯、山梨糖醇酐單棕櫚酸酯等之山梨糖醇酐 脂肪酸酯、甘油單辛酸酯、甘油單肉豆蔻酸酯、甘油單硬 脂酸酯等之甘油脂肪酸酯、十甘油醯單硬脂酸酯、十甘油 醯二硬脂酸酯、十甘油醯亞油酸酯等之聚甘油脂肪酸酯、 聚氧乙烯山梨糖醇酐單月桂酸酯、聚氧乙烯山梨糖醇酐單 油酸酯、聚氧乙烯山梨糖醇酐單硬脂酸酯、聚氧乙烯山梨 糖醇酐單棕櫚酸酯、聚氧乙烯山梨糖醇酐三油酸酯、聚氧 乙烯山梨糖醇酐三硬脂酸酯等之聚氧乙烯山梨糖醇酐脂肪 酸酯、聚氧乙烯山梨糖醇四硬脂酸酯、聚氧乙烯山梨糖醇 四油酸酯等之聚氧乙烯山梨糖醇脂肪酸酯、聚氧乙烯甘油 醯單硬脂酸酯等之聚氧乙烯甘油脂肪酸酯、聚乙二醇二硬 脂酸酯等之聚乙二醇脂肪酸酯、聚氧乙烯月桂醚等之聚氧 乙烯烷醚、聚氧乙烯聚氧丙二醇醚、聚氧乙烯聚氧丙烯丙 醚、聚氧乙烯聚氧丙烯鯨鱲醚等之聚氧乙烯聚氧丙烯烷醚 (請先閱讀背面之注意事項再填寫本頁) 11 -ϋ ϋ ϋ ϋ 一:口、 .^1 n I n ϋ -
經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -13- 1232749 Α7 Β7 經濟部智慧財產局員工消費合作社印製 五、發明說明(11 ) 、聚氧乙烯壬苯醚等之聚氧乙烯烷基苯醚、聚氧乙烯箆麻 油、聚氧乙烯硬化箆麻油(聚氧乙烯氫化箆麻油)等之聚 氧乙烯硬化箆麻油、聚氧乙烯山梨糖醇蜜蠟等之聚氧乙烯 蜜蠟衍生物、聚氧乙烯羊毛脂等之聚氧乙烯羊毛脂衍生物 、聚氧乙烯硬脂酸醯胺等之聚氧乙烯脂肪酸醯胺等之具有 H L B 6〜1 8者,陰離子界面活性劑例如鯨蠟基硫酸鈉 、月桂基硫酸鈉、油基硫酸鈉等之具有碳數1 0〜1 8個 烷基之烷基硫酸鹽、聚氧乙烯月桂基硫酸鈉等之乙烯氧之 平均附加莫耳數爲2〜4且烷基之碳數爲1 〇〜1 8個之 聚氧乙烯烷基醚硫酸鹽、月桂基磺基琥珀酸酯鈉等之烷基 碳數爲8〜18個之烷基磺基琥珀酸酯鹽、天然界之界面 活性劑例如卵磷脂、甘油磷脂、神經鞘磷脂等之神經鞘磷 脂,碳數1 2〜1 8個之脂肪酸之蔗糖脂肪酸酯等爲其典 型例。於本發明之製劑中,可將此些界面活性劑之一種或 二種以上組合添加。 較佳之界面活性劑爲聚氧乙烯山梨糖醇酐脂肪酸酯, 特佳者爲聚山梨酸酯20、 21、 4〇、6〇、65、 80、 81、 85,最佳者爲聚山梨酸酯2〇及80。 本發明之含G - C S F製劑中所添加之界面活性劑的 添加量,一般相對於G - C S F 1重量份爲以 〇 · 0〇0 1〜1 0重量份,較佳相對於G — C S F 1重 量份爲以0 · 0 1〜5重量份,較佳相對於G - C S F 1 重量爲以0·2〜2重量份。 本發明之G _ C S F製劑的Ρ Η較佳爲5〜7,更佳 (請先閱讀背面之注意事項再填寫本頁) -------訂---------
本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -14- 1232749 A7 B7 五、發明說明(12 ) 之PH爲5 · 5〜6 · 8,再佳之pH爲6〜6 . 7,最 佳之P Η爲6 · 5。 (請先閱讀背面之注意事項再填寫本頁) 於本發明之G - C S F製劑中,視所需亦可再含有稀 釋劑、助溶劑、賦形劑、ρ Η調整劑、無痛化劑、緩衝劑 、含硫還原劑、抗氧化劑等。例如,含硫還原劑可列舉Ν -乙醯半胱胺酸、Ν -乙醯高半胱胺酸、硫辛酸、硫基二 元醇、硫基乙醇胺、硫基甘油、硫基山梨糖醇、锍基乙酸 及其鹽、硫代硫酸鈉、谷胱甘肽、及碳數1〜7個之硫烷 酸等之具有氫硫基之含硫還原劑等。又,抗氧化劑爲紅山 梨酸、二丁基羥基甲苯、丁基羥基茴香醚、α-生育酚、 醋酸生育酚、L -抗壞血酸及其鹽、L -抗壞血酸棕櫚酸 酯、L -抗壞血酸硬脂酸酯、亞硫酸氫鈉、亞硫酸鈉、沒 食子酸三戊酯、沒食子酸丙酯或乙二胺四醋酸鈉(
E D T A )、焦磷酸鈉、偏磷酸鈉等之嵌合劑。更且,亦 可含有氯化鈉、氯化鉀、氯化鉀、氯化鈣、磷酸鈉、磷酸 鉀、碳酸氫鈉等之無機鹽、檸檬酸鈉、檸檬酸鉀、醋酸鈉 等之有機鹽等之通常所添加之成分。 經濟部智慧財產局員工消費合作社印製 本發明之G - C S F製劑爲包含溶液製劑、冷凍乾燥 製劑、噴霧乾燥製劑等。最佳爲冷凍乾燥製劑。 本發明之製劑爲將此些成分,於磷酸緩衝液(較佳爲 磷酸-氫鈉-磷酸二氫鈉系)和/或檸檬酸緩衝液(較佳 爲檸檬酸鈉之緩衝液)等之溶液製劑領域中公知的水性緩 衝液中溶解,調製成溶液製劑,或將如此所調製之溶液製 劑依據常法進行冷凍乾燥、或噴霧乾燥則可製造。 -15- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1232749 A7 B7 五、發明說明(13 ) 本發明之安定化之含G — C S F製劑通常爲以非經口 投予途徑,例如注射劑(皮下注射、靜脈注射、肌肉注射 )等、經皮、經粘膜、經鼻、經肺等進行投藥,且亦可經 口投予。 本發明之G - C S F製劑通常爲被收納於密封、經滅 菌之塑膠或玻璃容器中,且於使用時溶解於純水(注射用 滅菌水)中供使用。 本發明製劑中所含之G - C S F量可依據欲治療疾病 之種類、疾病之重症度、患者年齢等而決定,但一般最終 之投予濃度爲1〜100//g/m£,較佳爲1〇〜800 Mg/m£,更佳爲5〇〜50〇//g/m^。 本發明之製劑於感染症和癌之化學治療中,若於投予 抗生素、抗菌劑、抗癌劑等藥劑時同時投予,則可判知其 改善患者抵抗力、活性等免疫應答力爲基礎的防禦機能, 於臨床上極爲有用。因此,本發明之製劑可與此些藥劑倂 用投予。 本發明之G - C S F製劑爲如後述實施例所示般,於 進行2 5 °C — 3個月長期保存試驗或4 0 °C — 2個月長期 保存試驗後,或於進行5 0 °C - 1個月之加速試驗或6 0 °C 一 2週之加速試驗後,亦顯示出極爲良好的G - C S F 殘存率。又,於進行5 0 °C — 1個月之加速試驗後或6〇 °C 一 2週之加速試驗後,亦幾乎未觀察到G — C S F的甲 硫胺酸殘基氧化體之生成率。本發明之G - C S F製劑爲 於2 5 °C - 3個月長期保存試驗後之G - C S F殘存率爲 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -16 - (請先閱讀背面之注意事項再填寫本頁) 訂---------
經濟部智慧財產局員工消費合作社印製 1232749 A7 B7 五、發明說明(14 ) 9 0 %以上,較佳爲9 5 %以上,4 0 °C — 2個月長期保 存試驗後之G — C S F殘存率爲9 0%以上,較佳爲9 5 %以上,5 0 °C — 1個月之加速試驗後之G — C S F殘存 率爲90%以上,較佳爲95%以上,60 °C - 2週之加 速試驗後之G- C S F殘存率爲9 0%以上,較佳爲9 5 %以上,且5 0 °C — 1個月之加速試驗後或6 0 °C — 2週 之加速試驗之G - C S F的甲硫胺酸殘基氧化體生成率爲 1 %以下,較佳爲檢測界限以下。 本發明之製劑,由後述之實施例結果,可觀察到經由 添加由離胺酸、組胺酸、精胺酸、天冬胺酸、麩胺酸、蘇 胺酸、天冬醯胺所組成群中選出一種以上之胺基酸、及由 斥水性胺基酸中選出一種以上之胺基酸,則可特別令常溫 中長期保存後之G — C S F殘存率增加,且經由添加甲硫 胺酸,則可令G - C S F之甲硫胺酸殘基氧化體生成率爲 ‘檢測界限以下。本發明者等人雖未拘束於特定之理論,但 推測令所添加的甲硫胺酸代替G - C S F之甲硫胺酸殘基 被氧化,則可降低G - C S F之甲硫胺酸殘基氧化體生成 率。 更且,若根據本發明,特別於甲硫胺酸殘基之氧化體 生成中,於更易受影響,且微量具有生理活性、具有甲硫 胺酸殘基之生理活性蛋白質之組成物中添加甲硫胺酸,則 可防止該生理活性蛋白質之甲硫胺酸殘基氧化體之生成。 特別地,於該生理活性蛋白質組成物中’不含有其他蛋白 質作爲安定劑時,蛋白質組成物爲被冷凍乾燥時’或蛋白 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -17 - (請先閱讀背面之注意事項再填寫本頁) 訂---------
經濟部智慧財產局員工消費合作社印製 經濟部智慧財產局員工消費合作社印製 1232749 Α7 Β7 五、發明說明(15 ) 質組成物爲以溶液狀態之情形中,因爲易生成蛋白質之甲 硫胺酸殘基氧化體,故甲硫胺酸之添加爲有效的。 更且,於本發明之組成物中,添加其他一種以上之胺 基酸,則可抑制甲硫胺酸殘基的氧化體生成,且可製造生 理活性蛋白質之分解、凝集等被抑制之安定化之含有具甲 硫胺酸殘基生理活性蛋白質之組成物。 此時所添加之胺基酸可列舉離胺酸、組胺酸、精胺酸 、天冬胺酸、麩胺酸、苯基丙胺酸、色胺酸、白胺酸、異 白胺酸、纈胺酸、丙胺酸、脯胺酸、甘胺酸、絲胺酸、蘇 胺酸、天冬醯胺、麩胺醯胺、酪胺酸等,且較佳爲組胺酸 、精胺酸、苯基丙胺酸。 本發明之生理活性蛋白質可列例如。 細胞激動素、間白素(I L 一 1〜I L 一 1 3等)、 菌落刺激因子(粒性細胞菌落刺激因子(G - C S F )、 巨噬細胞落菌刺激因子(Μ - C S F )、粒性細胞/巨噬 細胞菌落刺激因子(G Μ - C S F )、促紅血球生成素( ΕΡΟ)等)、干擾素(IFN—a、々、τ等)、腫瘤 壞死因子(TNF - a、TNF — /3等)、轉形生長因子 (T G F )、血小板衍生長因子(P D G F )、L I F ( 白血病抑制因子)、ο n c 〇 s t a t i ο η Μ (〇S Μ )、移動抑制 因子(MIF)、化學激動素、IL — 8、LD78、 M C P - 1 等, 生理活性胜肽;胰島素、胰高血糖激素、副甲狀腺激 素(Ρ Τ Η )、促胃酸激素、選擇蛋白、膽激動素、胃抑 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -18- (請先閱讀背面之注意事項再填寫本頁) I II----訂· — II---- 經濟部智慧財產局員工消費合作社印製 1232749 A7 ______B7_ 五、發明說明(16 ) 制劑、多肽、P物質、促胃動素、脾多肽、神經降壓肽、 腸胰高血糖激素、促胃酸酸激素釋出胜肽、促成長素抑制 素—2 8、Dainolfin > Gallanin、Vallonin、胰抑制素、 ZeopSln等生物體酵素,於活性中心存在甲硫胺酸殘基之酵 素(例如,蘋果酸脫氫酶等)等,或其變異體。 本發明之生理活性蛋白質較佳爲細胞激動素或生理活 性胜肽,更佳爲G - C S F、促紅血球生成素等之菌落刺 激因子或P T Η,且再佳爲G - C S F、促紅血球生成素 或 Ρ Τ Η。 依據以下之實施例更詳細說明本發明,但本發明之範 圍並不限定於此。業者可根據本發明之記載進行各種變更 、修飾,且此些變更、修飾亦被包含於本發明。 實施例 試驗方法 將每玻璃小瓶之各原料添加量爲如下述表1及表2般 調製各調劑液,進行無菌過濾後,無菌地於各玻璃小瓶中 正確充塡以1毫升,並且供於冷凍乾燥。冷凍乾燥終了後 完全打栓,製成G - C S F冷凍乾燥製劑。 (請先閱讀背面之注意事項再填寫本頁) 11111111
本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -19· 1232749 A7 B7 五、發明說明(17 ) 經濟部智慧財產局員工消費合作社印製 適 度 尺 張 紙 本 pH緩衝劑 蘅寸 繼^ 3 以磷緩衝劑作 成 p Η6·5 聚山梨酯酸 0.1 mg 0.1 mg 甘露醇 5 Omg 5 Omg 甲硫胺酸 ο ο 精胺酸 1 Omg 1 Omg 苯基丙胺酸 1 Omg 1 Omg G-CSF 25 0 // g 250 // g 1 / 試料.1 試料.2 格 規 A4 S) N (C 準 標 家
gigglHQH 氍鑛扭 0 0 0
dsu-D Γ9Ϊ俗^ Μ E 0 m ^ smlo 3χπ〇ς 0 3m〇 3m〇i 3 7/ 001 ^ί歡si m κι π® 祭}蘅ili繫^ smlo 3ui〇g bJQso
3S0I g // 001 ,¢^ smlo 3ιπ〇ς
smor—I sso 3 7/ 001
ς·¾M SSI.0 以 ιπ〇ς (請先閱讀背面之注意事項再填寫本頁) gmoT—η
smoI 3 τ/ 001 9·¾誠
^1 ^1 ·ϋ ϋ ϋ 一一口γ ϋ ϋ -ϋ ^1 ϋ ·_ϋ I
Μ 公 97 -20- 1232749 A7 B7 五、發明說明(18 ) 經濟部智慧財產局員工消費合作社印製 p Η緩衝劑 蘅… 輕£ 露链 3 以磷緩衝劑作 成 pH6.5 以磷緩衝劑作 成 pH6.5 蘅 ^ 繼 ^ 聚山梨酯酸 0.1 mg 0.1 mg 0 · 1 mg 0.1 mg 甘露醇 5 Omg 5 Omg 5 Omg 5 Omg 甲硫胺酸 ο o 〇 〇 精胺酸 Omg Omg 1 Omg 1 Omg 1 ! 苯基丙胺酸 Omg 1 Omg Omg 1 Omg G-CSF 250 // g 2 5 0 // g 250 // g 250 β g 試料.7 試料.8 試料.9 — 試料.10 --------訂--------- (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -21 - 1232749 A7 B7 五、發明說明(19 ) 經濟部智慧財產局員工消費合作社印製 蘅10 蘅^ 蘅10 蘅10 蘅10 蘅^ 蘅^ 蘅10 蘅10 Wx to 戰|X| 輕£ to 職|Χ| 輕s 輕£ 輕S 輕£ ΐ|ττ|\Γ 繼^ 繼^ 繼^ 繼η 繼η 露怪 露怪 露怪 露怪 羧怪 鐵怪 餾 h\f\ b^C\ txQ tx〇 瀣 OJJ a ^ < OJJ a T—i ε 1 i UJJ S τ—Η UJJ a 1~\ a r—Η UJJ a ^―Η a \ < a ▼ 1 崎 S τ—Η WK 〇 Ο Ο 〇 〇 Ο Ο O Ο Ο 0J) a 〇 a ο a ο bJ3 a ο bD B O 〇J) Β ο bX) e ο W) a O &J0 a O a ο 扭 ν·〇 v〇 un wn v〇 ιη UO »〇 νη 氍 Ο Ο Ο Ο o Ο Ο O o Ο Μ 氍 氍 氍 氍 氍 氍 氍 氍 氍 鏗 m 應 b/Λ 猶 m n/a 羅 鍵 ΧλΛ Η< 嫕 x\Y H< 擻 氍 氍 氍 氍 氍 氍 氍 稍 E Ε: E E 稍 « 稍 浒 浒 浒 擀 浒 擗 (¾ bD bJQ όΧ) bJO & 0X1 bD D/) $ $ 0S) 00 U 〇 〇 〇 〇 〇 〇 Ο Ο 〇 〇 〇 〇 〇 〇 〇 〇 ο ο 〇 〇 〇 Ti τ-\ 龚 r — cn τ—Η 寸 τ—Η un r—i VD 1—i f Η 〇〇 T-\ 龚 σ\ r—i 〇 CSI 龚 Μ ^ζΣ- (W Μ S鍇銶)s S 0 9迄_要喊_呂滕忉2氍稍猶 (Μεο 9迄_要)职_0 一:贼驭調运騰忉氍狴贮稍齡 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1232749 A7 B7 五、發明說明(21 ) 經濟部智慧財產局員工消費合作社印製 uo vd m un VO K Q. Qh Q. 怪 繼 蘅 蘅 蘅 1ΐ|ηΤ\Γ 戰 Μ !ΐΙττ1\Γ Qh 繼 m 繼 露 廳 mn. 氍 bJO OS) 0J) a r—Η e τ—H a τ—H 彐 Ο 〇 〇 OJ) bJ!) 鑛 a a a 扭 CSI ) CN ) CO 4—> bJ!) a ! i CD s ο a \ i 〇 Vh di) bi3 a a S < ο , i O τ i 〇 r—H IDS] bi) CD ^=! B a a Oh o \ { O ^1 O r—H Uh bJ] bJ) U 1 〇 〇 〇 ϋ o H 0 1 H 〇 i Ή \ ] 寸 cn uo CO VO m • j (請先閱讀背面之注意事項再填寫本頁) % -------訂·--------
本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -24- 經濟部智慧財產局員工消費合作社印製 1232749 A7 ------B7______ 五、發明說明(22 ) 將如此無菌調製之含G - C S F冷凍乾燥製劑,於 6 〇 °C之恆溫槽內靜置2週及1個月,於5 0 °C之恆溫槽 內靜置1個月、2個月、3個月;於4 0 t:之恆溫槽內靜 置2個月、4個月、6個月;及於2 5 °C之恆溫槽內靜置 3個月、6個月。 將加速品製劑、及未加速品製劑以1毫升純水正確溶 解’作成下述方法的試驗試料。 根據下述之方法1測定玻璃小瓶中的G - C S F含量 (殘存率)。又,根據下述之方法2測定玻璃小瓶中的G 一 C s F甲硫胺酸殘基氧化體生成率。 方法] 試料爲使用C4逆相柱(4 · 6mmx2 5〇mm、 3 0 0 A ),並以移動相中使用純水、乙腈、三氟醋酸之 逆相系高速液體層析法測定G - C S F含量。注入相當於 5微克份量之G — CSF,並以乙腈之梯度將G—CSF 溶出,且以2 1 5 n m之波長進行分光學檢測。 使用本方法測定的G - C S F含量,並且根據下式, 算出6 0 °C — 2週,及5 0 °C — 1個月加速後及於6 0 °C 2週及1個月,於50t 1個月、2個月、3個月, 於4 0 °C 2個月、4個月、6個月;及於2 5 °C 3個 月、6個月保存時之G-CSF殘存率(%)。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公t ) -25- (請先閱讀背面之注意事項再填寫本頁)
^1 ϋ ·ϋ ϋ 1· I 一:口、 ϋ n I 1232749 A7 B7 五、發明說明(23 ) 殘存率f 〇/ 1 =(指定期間加速後之G - C S F含量)^ , n n ° ; 藏口速品之G-CSF含量)—-Xl〇° (請先閱讀背面之注意事項再填寫本頁) 百式料爲使用C 4逆相柱(4 · 6 m m x 2 5 0 m m、 3 0 A ),並以移動相中使用純水、乙腈、三氟醋酸之逆 相系高速液體層析法測定G - C S F來變化體及G —
C S F Me t殘基氧化體。以乙腈之梯度將G — CSF 溶出’且以2 1 5 n m之波長進行分光學檢測。 使用本方法所測定之G - C S F未變化體及G — C S F M e t殘基氧化體之波峰面積,且根據下式,算
出60°C —週、及50°C— 1個月加速後之G — CSF
Met殘基氧化體生成率(%)。 G - CSF Me t殘基氧化體生成率(%)= (G-CSF M e t殘基氧化體)
"T5—CSF未變化體)+ (未加速品;^G —fsF含量)X1UU 經濟部智慧財產局員工消費合作社印製 實施例1 :各種p Η對於G - C S F殘存率所造成之效果 將表1記載之各種P Η調製之試料1及試料2,以方 法1記載之式算出進行6 0°C — 2週,及5 0°C — 1個月 加速試驗後之G - C S F殘存率。所得結果示於表3。 -26- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 3 12 五 2749
、發明說明(24 )
PH6 · 5比pH7 · 4之配方,顯示出同等或更佳 的安定性。 #施例2 :各種胺基酸對於G - c S F殘存率所造成之效 果(1 ) 將添加表1記載之各種胺基酸所調製之試料3〜6 ( G— CSF含量1〇 ◦微克),及試料7〜10 (G — CSF含量250微克),以方法1記載之式算出進行 6〇C 一 2週,及5 0 〇C — 1個月加速試驗後之G — C S F殘存率。所得之結果示於表4及表5。 (請先閱讀背面之注咅?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 〔表4〕 含 100//g G — CSF 製劑 試料.3 試料.4 試料.5 試料.6 苯基丙胺酸 無添加 1 Omg 無添加 1 Omg 精胺酸 無添加 無添加 1 Omg 1 Omg 50 °C -1個月 7 2.9% 84.8% 8 2.4% 9 8.3 % 60 〇C -2 週 67.2% 7 7.9% 6 8.8% 9 5.0 % 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -27- 1232749 A7 B7 五、發明說明(25 ) L^5〕含 2 5 0 // g G - C S F 製劑 試料.7 試料.8 試料.9 試料.1 0 苯基丙胺酸 無添加 1 Omg 無添加 1 Omg 精胺酸 無添加 無添加 1 Omg 1 Omg 5〇 °C -1個月 7 6.6% 8 8.1% 9 6.3% 99.7% 60。。-2 週 74.0% 7 8.1% 90.7% 97.1% 於任一之G - C S F含量中,均以單獨添加苯基丙胺 酸、或單獨添加精胺酸,比無添加胺基酸之配方製劑令安 定性更爲提高,但並不夠充分。於倂用苯基丙胺酸與精胺 酸下,則察見安定性的顯著提高。 實施例3 :各種胺基酸對於G - C S F殘存率所造成之效 果(2 ) 將添加表1記載之各種胺基酸所調製之試料1 1〜 2 0 (胺基酸1爲苯基丙胺酸、胺基酸2爲添加離胺酸、 、組胺酸、精胺酸、天冬胺酸、麩胺酸、絲胺酸、蘇胺酸 、酪胺酸、天冬醯胺及麩胺醯胺之任何一種)、及試料 2 1〜3 3 (胺基酸1爲精胺酸、胺基酸2爲添加丙胺酸 、纈胺酸、白胺酸、異白胺酸、甲硫胺酸、色胺酸、苯基 丙胺酸、脯胺酸、甘胺酸、絲胺酸、蘇胺酸、天冬醯胺及 麩胺醯胺之任何一種),以方法1記載之式算出進行6 0 °C 一 2週、及5 0 °C — 1個月加速試驗後之G — C S F殘 存率。所得之結果示於表6。 本紙張尺度適用中國國家標準(CNS)A4規格(210 χ 297公釐) -28 - (請先閱讀背面之注意事項再填寫本頁) - · 經濟部智慧財產局員工消費合作社印製 1232749 五、發明說明(26 A7 B7 經濟部智慧財產局員工消費合作社印製 〔表6 〕 50 °C -1個月 60 °C -2 週 試料.11 9 2.8% 91.2% 試料.1 2 9 8.8% 97.5% 試料.1 3 9 8.0% 9 6.0% 試料.1 4 9 5.7% 9 6.7% 試料.1 5 95.6% 94.0% 試料.1 6 8 8.4% 87.8% 試料.1 7 9 6.4% 90.7% 試料.1 8 8 4.6% 81.7% 試料.1 9 9 5.0% 95.3% 試料.20 8 9.8% 8 7.2% (請先閱讀背面之注意事項再填寫本頁) ^1 ϋ ϋ I^eJ n ϋ ϋ I ϋ 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1232749 A7 ----------B7 五、發明說明(27 ) L47 ] 5 0 °C -1個月 60 〇C -2 週 —料· 2 1 8 9.0% 8 4.4% —料.22 8 8.9% 8 6.5% —式料· 2 3 96.3% 9 6.2% ^料· 2 4 8 8.5% 8 9.3% ----料· 2 5 95.5% 8 8.5% 式料.26 101.4% 9 8.6% 式料.27 97.0% 95.7% 試料.2 8 8 9.4% 8 2.5% 試料.29 90.9% 71.2% 試料.30 89.2% 8 5.2% 試料.3 1 90.6% 8 7.3% 試料.32 94.0% 8 8.6% 試料.3 3 90.1% 84.6% -1 -------------------訂----- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 於苯基丙胺酸與離胺酸、苯基丙胺酸與組胺酸、苯基 丙胺酸與精胺酸、苯基丙胺酸與天冬胺酸、苯基丙胺酸與 麩胺酸、苯基丙胺酸與蘇胺酸、苯基丙胺酸與天冬醯胺之 組合、及精胺酸與酪胺酸、精胺酸與色胺酸、精胺酸與苯 基丙胺酸之組合中分別觀察到顯著的長期保存安定性。 實施例4 :長期保存試驗 對於含有苯基丙胺酸1 0毫克、精胺酸1 〇毫克、甲 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -30- ' 1232749 A7 _____ __B7__— 一 五、發明說明(29 ) 5〇°C 一 1個月保存後均觀察到G 一 c s F M e t殘基 氧化體之生成,但經由添加1毫克以上的甲硫胺酸’則即 使於長期保存後亦可完全抑制G - C S F M e t殘基氧 化體之生成。 又,以方法2記載之式所算出之G—CSF Met 殘基氧化體生成率之結果示於表9。 〔表9〕 試料.34 試料.35 試料.36 Met Omg Met 0.1 mg Met lmg 5〇 °C -1個月 1.2% N.D. N.D. 60 °C -2 週 1.7% N.D. N.D. N · D ·:檢測界限以下 如此’經由添加0 · 1毫克以上之甲硫胺酸,則可完 全抑制G - C S F M e t殘基氧化體之生成。 實施例6 :對於副甲狀腺激素溶液製劑添加甲硫胺酸所造 成之甲硫胺酸殘基氧化抑制作用 將含有2 0 0微克/毫升之具1〜8 4個殘基之副甲 狀腺激素(以下簡述爲P T Η )(以 W〇 9 0 1 4 4 1 5記載之方法製造),且每玻璃小瓶 之各原料添加量爲如下述表1 0般所調製之試料3 7〜試 料3 9之各調劑液,進行無菌過濾後,無菌地於各玻璃小 本紙張尺度適用中關家標準(CNS)A4規格(210 X 297公釐) --- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1232749 A7 ____B7 五、發明說明(31 ) ’經由對於製劑中添加甲硫胺酸,對於其他的化學分解反 應不會造成影響,且僅對於蛋白質中之甲硫胺酸殘基氧化 體生成抑制可造成專一性地改善。 I業上之利用領域 本發明之G - C S F製劑,即使於長期保存後可令G - C S F的殘存率爲極高,且爲幾乎可完全抑制G — C S F之甲硫胺酸殘基氧化體生成率的安定製劑。 (請先閱讀背面之注咅?事項再填寫本頁) 1111111.
經濟部智慧財產局員工消費合作社印製 -34- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)
Claims (1)
- 六、申請專利範圍 …"…一一~τ〒:第89103623號專利申請案 一 .1 B sl|中文申請專利範圍修正本 J . , J 民國93年12月17日修正 (請先閱讀背面之注意事項再填寫本頁) 1 · 一種安定的G - C S F醫藥組成物,其特徵含有 1種以上選自離胺酸、組胺酸、精胺酸、天冬胺酸、麩胺 酸、蘇胺酸、天冬醯胺所成群之胺基酸、及1種以上選自 斥水性胺基酸之胺基酸、及甲硫胺酸。 2 ·如申請專利範圍第1項之G - C S F醫藥組成物 ’其爲2 5 C - 3個月長期保存§式驗後之G — C S F殘存 率爲9 0 %以上,4 0 t: — 2個月長期保存試驗後之G — C S F殘存率爲9 0 %以上,5 0 °C — 1個月之加速試驗 後之G - C S F殘存率爲9 0 %以上,6 0 °C — 2週之加 速試驗後之G — C S F殘存率爲9 0 %且5 0。(: 一 1個月 之加速試驗後或6 0 °C - 2週之加速試驗後之G - C S F 的甲硫胺酸殘基氧化體生成率爲1 %以下。 3 ·如申請專利範圍第1項之G - C S F醫藥組成物 ’其中斥水性胺基酸爲選自苯基丙胺酸、色胺酸及白胺酸 〇 經濟部智慧財產局員工消費合作社印製 4 ·如申請專利範圍第1項之G - C S F醫藥組成物 ’其爲含有1種以上選自離胺酸、組胺酸、精胺酸、天冬 胺酸、麩胺酸所成群之胺基酸、及1種以上選自苯基丙胺 酸、色胺酸及白胺酸所成群之胺基酸、及甲硫胺酸。 5 .如申請專利範圍第1項之G - C S F醫藥組成物 ’其爲含有苯基丙胺酸、精胺酸及甲硫胺酸。 本紙張尺度適用中國國家摞準j cNS ) A4Wt^ ( 210X 297-/^¾ ) 1232749 A8 Βδ C8 _ D8 六、申請專利範圍 6 .如申請專利範圍第1〜5項中任一項之G -C S F醫藥組成物,其中安定劑爲實質上不含有蛋白質。 (請先閲讀背面之注意事項再填寫本頁) 7 .如申請專利範圍第1〜5項中任一項之G -C S F醫藥組成物,其爲冷凍乾燥醫藥組成物。 8 .如申請專利範圍第1〜5項中任一項之G -C S F醫藥組成物,其更含有甘露糖醇。 9 .如申請專利範圍第1〜5項任一項之G - C S F 醫藥組成物,其爲更含有界面活性劑。 1 0 .如申請專利範圍第9項之G - C S F醫藥組成 物,其中界面活性劑爲聚環氧乙烷山梨聚糖烷酯。 1 1 .如申_專利範圍第1 〇項之G — C S F醫藥組 成物,其中界面活性劑爲聚山梨酸酯2 0及/或8 0。 1 2 .如申請專利範圍第1〜5項中任一項之G -CSF醫藥組成物,其中pH爲5〜7。 1 3 .如申請專利範圍第1 2項之G — C S F醫藥組 成物,其中pH爲5 . 5〜6 · 8。 1 4 .如申請專利範圍第1 3項之G - C S F醫藥組 成物,其中pH爲6.5。 經濟部智慧財產局員工消費合作社印製 1 5 .如申請專利範圍第1〜5項中任一項之G -C S F醫藥組成物,其中G — C S F爲由CHO細胞所產 生的 G — C. S F。 16 .一種安定的G一CSF醫藥組成物,其特徵爲 含有1種以上選自離胺酸 '組胺酸、精胺酸、天冬胺酸、 麩胺酸、蘇胺酸、天冬醯胺所成群之胺基酸、及一種以上 本紙張尺度適用中國國家標準(CNS ) A4規格(公釐) -2- 1232749 A8 B8 C8 D8 六、申請專利範圍 選自斥水性胺基酸之胺基酸,且ρ Η 5〜7,其中 2 5 °C - 3個月長期保存試驗後之G - c S F殘存率爲 9 0 %以上’ 4 0 °C — 2個月長期保持試驗後之〇 一 C S F殘存率爲9 0 %以上’ 5 0 °c — 1個月之加速試驗 後之G - C S F殘存率爲9 0 %以上,6 0 t — 2週之加 速試驗後之G - C S F殘存率爲9 〇 %以上。 1 7 · —種安定的G - C S F醫藥組成物,其特徵爲 含有1種以上選自離胺酸、組胺酸、精胺酸、天冬胺酸、 鍵胺酸所成群之胺基酸、及1種以上選自苯基丙胺酸、色 胺酸及白胺酸所成群之胺基酸,且p Η爲5〜7,其中 2 5 °C - 3個月長期保存試驗後之G - C S F殘存率爲 9 0 %以上,4 0 °C - 2個月長期保存試驗後之G 一 C S F殘存率爲9 0 %以上,5 0 °C - 1個月之加速試驗 後之G - CSF殘存率爲90%以上,60 °C — 2週之加 速試驗後之G - C S F殘存率爲9 0 %以上。 1 8 ·如申請專利範圍第1 6或1 7項之G — C S F 醫藥組成物,其中p Η爲6 . 5。 1 9 ·如申請專利範圍第1項之G — C S F醫藥組成 物,其爲實質上不生成甲硫胺酸氧化物。 2 〇 ·如申請專利範圍第1項之G - C S F醫藥組成 物,其爲含有甲硫胺酸和其他一種以上之胺基酸,且實質 上不生成蛋胺酸氧化物。 2 1 ·如申請專利範圍第1 9或2 0項之G — C S F 醫藥組成物,其中安定劑爲實質上不含有蛋白質。 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) -3 - --------—— (請先閱讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 1232749 Α8 Β8 C8 D8 六、申請專利範圍 2 2 · —種抑制蛋白質之甲硫胺酸殘基氧化物生成的 方法’其特徵爲於含有具甲硫胺酸殘基生理活性蛋白質之 組成物中’添加甲硫胺酸,其中該生理活性蛋白質爲G 一 C. S F 或 Ρ Τ Η。 2 3 .如申請專利範圍第2 2項之方法,其中安定劑 爲不含其他蛋白質。 2 4 .如申請專利範圍第2 2項之方法,其中含有甲 硫胺酸殘基的生理活性蛋白質之組成物爲被冷凍乾燥或爲 溶液狀態。 C— (請先閱讀背面之注意事項再填寫本頁} 、1Τ 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -4 -
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11052314A JP2000247903A (ja) | 1999-03-01 | 1999-03-01 | 長期安定化製剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI232749B true TWI232749B (en) | 2005-05-21 |
Family
ID=12911333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW089103623A TWI232749B (en) | 1999-03-01 | 2000-03-01 | Preparations stabilized over long time |
Country Status (16)
Country | Link |
---|---|
US (1) | US6908610B1 (zh) |
EP (2) | EP1197221B1 (zh) |
JP (2) | JP2000247903A (zh) |
KR (2) | KR100656125B1 (zh) |
CN (3) | CN1879875B (zh) |
AT (1) | ATE326233T1 (zh) |
AU (1) | AU772604B2 (zh) |
CA (1) | CA2381229C (zh) |
CY (1) | CY1105528T1 (zh) |
DE (1) | DE60028037T2 (zh) |
DK (1) | DK1197221T3 (zh) |
ES (1) | ES2263450T3 (zh) |
HK (3) | HK1045652A1 (zh) |
PT (1) | PT1197221E (zh) |
TW (1) | TWI232749B (zh) |
WO (1) | WO2000051629A1 (zh) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001048117A1 (fr) * | 1999-12-24 | 2001-07-05 | Otsuka Pharmaceutical Co., Ltd. | Compositions seches contenant un acide amine hydrophobe |
AU2001236005A1 (en) | 2000-02-29 | 2001-09-12 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilized over long time |
EP1525889A1 (en) * | 2000-05-15 | 2005-04-27 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivative |
EP1329224A4 (en) * | 2000-09-01 | 2004-04-14 | Chugai Pharmaceutical Co Ltd | PREPARATIONS OF STABILIZED SOLUTIONS OVER A LONG PERIOD OF TIME |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
DE60139944D1 (de) | 2000-10-12 | 2009-10-29 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
US20030104996A1 (en) | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
DE10149030A1 (de) * | 2001-10-05 | 2003-04-10 | Viscum Ag | Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin |
EP1458408B1 (en) | 2001-12-21 | 2009-04-15 | Novo Nordisk Health Care AG | Liquid composition of factor vii polypeptides |
KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
US7351800B2 (en) * | 2002-02-28 | 2008-04-01 | Nipro Corporation | Stabilized albumin preparations |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
EP1517698B2 (en) | 2002-06-21 | 2017-12-06 | Novo Nordisk Health Care AG | STABILISED SOLID COMPOSITIONS OF FACTOR VIIa POLYPEPTIDES |
US6803046B2 (en) * | 2002-08-16 | 2004-10-12 | Bracco International B.V. | Sincalide formulations |
JP4489591B2 (ja) * | 2002-08-27 | 2010-06-23 | 中外製薬株式会社 | タンパク質溶液製剤の安定化方法 |
JP4607010B2 (ja) | 2003-02-28 | 2011-01-05 | 中外製薬株式会社 | タンパク質含有安定化製剤 |
JP2006524195A (ja) * | 2003-03-18 | 2006-10-26 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Vii因子ポリペプチドの液状水性医薬組成物 |
US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
JP4869064B2 (ja) * | 2003-04-04 | 2012-02-01 | ジェネンテック, インコーポレイテッド | 高濃度抗体及びタンパク質製剤 |
WO2004103398A1 (en) * | 2003-05-23 | 2004-12-02 | Novo Nordisk Health Care Ag | Protein stabilization in solution |
ATE446768T1 (de) * | 2003-07-01 | 2009-11-15 | Novo Nordisk Healthcare Ag | Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden |
FR2857267B1 (fr) * | 2003-07-09 | 2006-03-10 | Lab Francais Du Fractionnement | Formulation stabilisante et solubilisante pour les proteines cryoprecipitables. |
DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
EP1656158B1 (en) * | 2003-08-14 | 2016-03-09 | Novo Nordisk Health Care AG | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
JP2007534633A (ja) * | 2003-11-10 | 2007-11-29 | アライバ−プロメティック インコーポレイティド | ヒト・アルファ1−抗トリプシン製剤 |
CA2545855A1 (en) * | 2003-11-14 | 2005-06-02 | Baxter International Inc. | Alpha 1-antitrypsin compositions and treatment methods using such compositions |
EP2298287B1 (en) * | 2003-12-19 | 2018-04-11 | Novo Nordisk Health Care AG | Stabilised compositions of factor VII polypeptides |
DE102004011663B4 (de) * | 2004-03-10 | 2006-04-27 | Bioceuticals Arzneimittel Ag | Erythropoietin-Flüssigformulierung |
JP2005310840A (ja) | 2004-04-16 | 2005-11-04 | Toshiba Corp | 磁気ランダムアクセスメモリ |
US20060293243A1 (en) * | 2005-06-17 | 2006-12-28 | Navneet Puri | Stable, buffered, pharmaceutical compositions including motilin-like peptides |
US7534753B2 (en) * | 2006-01-12 | 2009-05-19 | Air Products And Chemicals, Inc. | pH buffered aqueous cleaning composition and method for removing photoresist residue |
TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
WO2007108505A1 (ja) * | 2006-03-22 | 2007-09-27 | Chugai Seiyaku Kabushiki Kaisha | エリスロポエチン溶液製剤 |
AU2008235044B2 (en) * | 2007-04-05 | 2011-08-25 | Sandoz Ag | Stable aqueous G-CSF formulations |
US20080286471A1 (en) * | 2007-05-18 | 2008-11-20 | Doubleday Marc D | Protective gel for an electrical connection |
EP2170268A2 (en) * | 2007-06-25 | 2010-04-07 | Amgen, Inc. | Compositions of specific binding agents to hepatocyte growth factor |
US8617568B2 (en) | 2007-07-10 | 2013-12-31 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
KR20100111682A (ko) | 2008-01-09 | 2010-10-15 | 사노피-아벤티스 도이칠란트 게엠베하 | 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체 |
MX2011002372A (es) * | 2008-09-10 | 2011-04-04 | Genentech Inc | Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas. |
KR101820024B1 (ko) | 2008-10-17 | 2018-01-18 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린과 glp-1 효능제의 병용물 |
EP2403874A1 (en) | 2009-03-06 | 2012-01-11 | Genentech, Inc. | Antibody formulation |
HUE037735T2 (hu) | 2009-11-13 | 2018-09-28 | Sanofi Aventis Deutschland | DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény |
ES2534191T3 (es) | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
EA201891433A3 (ru) * | 2010-01-15 | 2019-02-28 | Кирин-Эмджен, Инк. | Состав антитела и терапевтические режимы |
TWI609698B (zh) * | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | 穩定化的含抗體溶液製劑 |
CA3101298A1 (en) | 2010-03-01 | 2011-09-09 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
EP2399572A1 (en) | 2010-06-22 | 2011-12-28 | Sandoz AG | Long-term storage of non-glycosylated recombinant human G-CSF |
BR112013004756B1 (pt) | 2010-08-30 | 2020-04-28 | Sanofi Aventis Deutschland | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 |
TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
CN102028661B (zh) * | 2010-12-31 | 2012-05-23 | 山东新时代药业有限公司 | 聚乙二醇化重组人粒细胞集落刺激因子冻干粉针剂及其制备方法 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
RU2650616C2 (ru) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
WO2013142336A1 (en) * | 2012-03-21 | 2013-09-26 | Miller Leonard B | Combination therapy to improve joint, tendon, and ligament healing |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
US9663563B2 (en) | 2013-03-12 | 2017-05-30 | Sumitomo Dainippon Pharma Co., Ltd. | Aqueous liquid composition |
CA3135558A1 (en) * | 2013-03-13 | 2014-10-02 | Genentech, Inc. | Prevention of protein oxidation in a composition |
BR112015022484A2 (pt) * | 2013-03-13 | 2017-07-18 | Genentech Inc | formulações com oxidação reduzida |
US20140314778A1 (en) | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
JP6461005B2 (ja) * | 2013-11-21 | 2019-01-30 | 協和メデックス株式会社 | 血清又は血漿中の低密度リポ蛋白の凍結乾燥による変性抑制剤及び変性抑制方法 |
US9895424B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
US9839692B2 (en) | 2014-01-09 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
SG11201604706TA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart |
JP6970615B2 (ja) | 2014-12-12 | 2021-11-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン/リキシセナチド固定比処方 |
CN104524553B (zh) * | 2014-12-12 | 2015-07-29 | 薛传校 | 一种长效促***注射液 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
US11110063B2 (en) | 2017-08-25 | 2021-09-07 | MAIA Pharmaceuticals, Inc. | Storage stable sincalide formulations |
JP6577683B2 (ja) * | 2017-09-22 | 2019-09-18 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
CN109627300B (zh) * | 2019-02-18 | 2022-08-05 | 浙江新银象生物工程有限公司 | Nisin溶液稳定剂开发及应用 |
EP4110370A4 (en) * | 2020-03-30 | 2023-06-07 | Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. | FORMULATIONS OF HUMAN PARATHYROID HORMONE (PTH) AND METHODS OF MANUFACTURE THEREOF |
WO2023066988A1 (en) | 2021-10-19 | 2023-04-27 | Sandoz Ag | Glass container with low aluminum content and gas overlay to prevent oxidation of sensitive therapeutic agents |
CN115624187B (zh) * | 2022-12-08 | 2023-04-04 | 北京第一生物科技开发有限公司 | 牛脾肽粉在改善睡眠中的用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3228502A1 (de) * | 1982-07-30 | 1984-02-02 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung des c1-inaktivators und seine verwendung |
JP2577744B2 (ja) * | 1986-07-18 | 1997-02-05 | 中外製薬株式会社 | 安定な顆粒球コロニ−刺激因子含有製剤 |
DE3729863A1 (de) | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
JP2974722B2 (ja) | 1990-04-03 | 1999-11-10 | 帝国臓器製薬株式会社 | カルシトニン注射液 |
US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
GB9120304D0 (en) * | 1991-09-24 | 1991-11-06 | Erba Carlo Spa | Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor |
US5192743A (en) | 1992-01-16 | 1993-03-09 | Genentech, Inc. | Reconstitutable lyophilized protein formulation |
JPH05331071A (ja) | 1992-01-17 | 1993-12-14 | Asahi Chem Ind Co Ltd | カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法 |
IL107887A (en) | 1992-12-08 | 2003-07-06 | Ambi Inc | Stabilized lanthionine containing bacteriocin compositions |
DE4242863A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
US5780431A (en) * | 1996-09-20 | 1998-07-14 | Neurobiological Technologies, Inc. | Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form |
TW518235B (en) * | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
PT1491208E (pt) * | 1999-10-04 | 2010-05-12 | Novartis Vaccines & Diagnostic | Composições farmacêuticas contendo polipéptido líquidas estabilizadas |
-
1999
- 1999-03-01 JP JP11052314A patent/JP2000247903A/ja active Pending
-
2000
- 2000-02-29 CN CN2006100923765A patent/CN1879875B/zh not_active Expired - Lifetime
- 2000-02-29 CN CNA2009101329481A patent/CN101537173A/zh active Pending
- 2000-02-29 KR KR1020017011145A patent/KR100656125B1/ko active IP Right Grant
- 2000-02-29 ES ES00905397T patent/ES2263450T3/es not_active Expired - Lifetime
- 2000-02-29 WO PCT/JP2000/001160 patent/WO2000051629A1/ja active IP Right Grant
- 2000-02-29 CA CA2381229A patent/CA2381229C/en not_active Expired - Lifetime
- 2000-02-29 DK DK00905397T patent/DK1197221T3/da active
- 2000-02-29 PT PT00905397T patent/PT1197221E/pt unknown
- 2000-02-29 EP EP00905397A patent/EP1197221B1/en not_active Expired - Lifetime
- 2000-02-29 DE DE60028037T patent/DE60028037T2/de not_active Expired - Lifetime
- 2000-02-29 US US09/914,641 patent/US6908610B1/en not_active Expired - Lifetime
- 2000-02-29 AU AU26954/00A patent/AU772604B2/en not_active Expired
- 2000-02-29 AT AT00905397T patent/ATE326233T1/de active
- 2000-02-29 KR KR1020057017282A patent/KR100731559B1/ko active IP Right Grant
- 2000-02-29 CN CN00804421A patent/CN1342087A/zh active Pending
- 2000-02-29 EP EP06010059.1A patent/EP1700605B1/en not_active Expired - Lifetime
- 2000-02-29 JP JP2000602295A patent/JP4607336B2/ja not_active Expired - Lifetime
- 2000-03-01 TW TW089103623A patent/TWI232749B/zh not_active IP Right Cessation
-
2002
- 2002-09-27 HK HK02107149.3A patent/HK1045652A1/zh unknown
- 2002-10-16 HK HK02107478.4A patent/HK1046239B/zh not_active IP Right Cessation
-
2006
- 2006-08-02 CY CY20061101080T patent/CY1105528T1/el unknown
-
2007
- 2007-06-15 HK HK07106471.8A patent/HK1098963A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1700605B1 (en) | 2014-04-30 |
EP1197221A4 (en) | 2003-01-29 |
PT1197221E (pt) | 2006-08-31 |
AU2695400A (en) | 2000-09-21 |
HK1098963A1 (en) | 2007-08-03 |
KR20050099637A (ko) | 2005-10-14 |
EP1700605A2 (en) | 2006-09-13 |
JP4607336B2 (ja) | 2011-01-05 |
DK1197221T3 (da) | 2006-11-13 |
EP1197221A1 (en) | 2002-04-17 |
HK1045652A1 (zh) | 2002-12-06 |
ES2263450T3 (es) | 2006-12-16 |
CA2381229C (en) | 2010-10-26 |
HK1046239B (zh) | 2006-08-18 |
CN1342087A (zh) | 2002-03-27 |
WO2000051629A1 (fr) | 2000-09-08 |
JP2000247903A (ja) | 2000-09-12 |
DE60028037T2 (de) | 2006-12-21 |
AU772604B2 (en) | 2004-05-06 |
KR100656125B1 (ko) | 2006-12-12 |
CY1105528T1 (el) | 2010-07-28 |
KR20010102469A (ko) | 2001-11-15 |
HK1046239A1 (en) | 2003-01-03 |
KR100731559B1 (ko) | 2007-06-22 |
CN1879875A (zh) | 2006-12-20 |
DE60028037D1 (de) | 2006-06-22 |
CN1879875B (zh) | 2010-08-25 |
US6908610B1 (en) | 2005-06-21 |
EP1197221B1 (en) | 2006-05-17 |
EP1700605A3 (en) | 2007-06-13 |
CA2381229A1 (en) | 2000-09-08 |
ATE326233T1 (de) | 2006-06-15 |
CN101537173A (zh) | 2009-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI232749B (en) | Preparations stabilized over long time | |
ES2326498T3 (es) | Formulacion liquida de g-csf. | |
US7163671B2 (en) | Long-term stabilized formulations | |
JP2007204498A (ja) | 長期安定化製剤 | |
AU2006235962A1 (en) | Solution formulations having long-term stability | |
JP3895109B2 (ja) | 蛋白非添加製剤 | |
EP0364491A1 (en) | Stabilized formulations of gamma interferons | |
JP2577744B2 (ja) | 安定な顆粒球コロニ−刺激因子含有製剤 | |
JP2577742B2 (ja) | 安定な顆粒球コロニ−刺激因子含有製剤 | |
JPH07145070A (ja) | 医薬組成物 | |
EP3125922B1 (en) | Liquid pharmaceutical composition of conjugated erythropoietin | |
JP4454571B2 (ja) | 蛋白非添加製剤 | |
JP2629000B2 (ja) | 安定な顆粒球コロニー刺激因子含有製剤 | |
JPS63146827A (ja) | 安定な顆粒球コロニ−刺激因子含有製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Expiration of patent term of an invention patent |